Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299104 | 0.74 | PTPN1 (0.34) | — | |
| SCHEMBL12299117 | 0.72 | TERT (0.30) | TERT | |
| SCHEMBL11642510 | 0.71 | — | — | |
| SCHEMBL5568400 | 0.67 | — | — | |
| SCHEMBL2359557 | 0.67 | — | — | |
| SCHEMBL12299130 | 0.66 | — | — | |
| SCHEMBL12329079 | 0.66 | — | — | |
| SCHEMBL9284550 | 0.64 | — | — | |
| SCHEMBL7944681 | 0.63 | — | — | |
| SCHEMBL7545754 | 0.63 | PARP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729060-B2 | Macrocyclic polyoxazole compounds and use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
| WO-2009018549-A1 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | MCL1, MKI67, NCL | TERT 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.